As Filed with the Securities and Exchange Commission on October 17, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) (Primary Standard Industrial Classification Code Number) Delaware 2834 87-0455038 (I.R.S. Employer Identification Number) 1900 Lake Park Drive, Suite 380, Smyrna, Georgia 30080, (678) 384-7220 (Address, incl ...

Core Viewpoint - GeoVax Labs reported strong second quarter 2025 results with significant revenue growth but raised concerns about increased operating costs and cash reserves [1][5][10] Financial Performance - GAAP revenue reached $0.85 million, exceeding analyst estimates of $0.39 million, marking a year-over-year increase of 183.6% from $0.30 million in Q2 2024 [2][5] - GAAP earnings per share were a loss of $(0.35), slightly worse than the expected $(0.34) but a significant improvement from $(1.99) in Q2 2024, reflecting an 82.4% year-over-year improvement [2][6] - Net loss for the quarter was $(5.37) million, a slight increase from $(5.06) million in Q2 2024, while research and development expenses rose by 10.5% to $4.73 million [2][6] Business Overview - GeoVax specializes in developing vaccines and immunotherapies for infectious diseases and cancer, focusing on unmet medical needs [3] - The clinical pipeline includes three main product families: GEO-CM04S1 (COVID-19 vaccine), GEO-MVA (mpox and smallpox vaccine), and Gedeptin (gene-directed immunotherapy for cancers) [3] Strategic Focus - The company aims to accelerate clinical trial progress, expand its intellectual property portfolio, and improve manufacturing scalability [4] - Key success factors include advancing clinical trials, securing regulatory approvals, and forming strategic partnerships [4] Pipeline Progress - Revenue growth was driven by government contract revenues from the BARDA/RRPV Project NextGen award, which has since been terminated [5][10] - The GEO-MVA vaccine received positive regulatory feedback from the EMA, with plans to initiate a pivotal Phase 3 trial in late 2026, representing a market opportunity over $10 billion [7] - The GEO-CM04S1 vaccine is targeting immunocompromised patients, showing enhanced immune responses in clinical trials [8] Manufacturing and Intellectual Property - GeoVax is developing scalable vaccine manufacturing methods to address supply bottlenecks and has secured new U.S. patents for a malaria vaccine and expanded Gedeptin use [9] Future Outlook - The company ended the quarter with $3.09 million in cash, down from $5.51 million, and raised $5.6 million through a public offering to extend its cash runway [10] - Management did not provide formal guidance but emphasized advancing vaccine and oncology programs and building U.S.-based manufacturing capacity [11]

As filed with the Securities and Exchange Commission on August 6, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 87-0455038 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 1900 Lake Park Drive, Su ...